The CJC-1295 record, ranked by what it can carry

What this site is

Order CJC-1295 is an editorial desk that puts one compound's evidence in order: the peer-reviewed research on CJC-1295, ranked and arranged by weight. No clinic runs here, no clinicians are on staff, and no medical advice is issued; nothing is manufactured, supplied, or sold. The work is a sourced reading of published science — an arrangement of the record, not a service.

The approach is curatorial: the CJC-1295 literature is a small set of high-quality, unequal-weight findings, and this site arranges them the way an editor arranges a front page — the strongest result largest, the supporting context smaller, every card carrying its source. The pulsatility finding leads because it is the most interesting thing the record establishes; the DAC-versus-no-DAC distinction gets its own page because conflating the two is the field's most common error.

What the name means

The 'Order' in Order CJC-1295 is editorial, not transactional. This is a desk that has ordered the evidence into a hierarchy — a research noticeboard, not a storefront. The site does not sell CJC-1295, does not link to vendors, and does not quote prices. If you arrived looking to buy something, this is the wrong kind of page; if you arrived to understand what the studies actually measured, the digest is built for you.

CJC-1295 is an unapproved research chemical. It is not approved for human use by the FDA or any major regulator, and it is prohibited at all times in sport under WADA Section S2. Nothing here should be read as encouragement to use it; the content describes what researchers administered to which species and what they observed.

How we handle the research

Every quantitative claim on this site is tied to a numbered citation, and the references page links each one to a DOI or PubMed record. Where the evidence is strong — the multi-day pharmacokinetics, the preserved pulsatility, the rodent origin work — we say so plainly. Where it is thin or absent — long-term safety, validated clinical outcomes in healthy adults, the CJC-1295/ipamorelin combination as a treatment — we mark the gap rather than paper over it. A digest that only reports the favorable findings is not a digest worth trusting.